Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
NCT03626688 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
- Lead sponsor
- United Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 24, 2019
- Completion date
- December 31, 2025
- Enrollment
- 687 (actual)
- Sites
- 209
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular diseases, connective tissue diseases, familial primary pulmonary hypertension, hypertension, hypertension, pulmonary, lung diseases, pah, pulmonary arterial hypertension, pulmonary hypertension, respiratory tract disease, vascular diseases